Atara Biotherapeutics (ATRA) Profit After Tax (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Profit After Tax data on file, last reported at -$4.1 million in Q1 2026.

• Quarterly Profit After Tax fell 110.91% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.5 million (up 40.27% YoY) and the FY2025 annual result came in at $32.7 million, up 138.28% from the prior year.
• Profit After Tax slipped to -$4.1 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
• A 5-year average of -$33.0 million and a median of -$21.9 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 485.08% — and 2025, when it surged 219.68%.
• Tracing ATRA's Profit After Tax over 5 years: stood at -$74.6 million in 2022, then grew by 19.43% to -$60.1 million in 2023, then jumped by 78.5% to -$12.9 million in 2024, then surged by 73.68% to -$3.4 million in 2025, then declined by 21.94% to -$4.1 million in 2026.
• The last three Profit After Tax figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.